The cumulative incidence of any SARS-CoV-2 infection in the immediate NVX-CoV2373 group (receiving the vaccine in the initial series and placebo in the crossover series) and delayed NVX-CoV2373 group (receiving placebo in the initial series and the vaccine in the crossover series) in the post-crossover analysis population. Incidence was estimated by KaplanMeir curves based on follow-up time from the primary analysis. Insets show data on an enlarged y axis.
